Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - ethyl and methyl esters of canola oil; non-ionic surfactant - emulsifiable concentrate - ethyl and methyl esters of canola oil active active 704.0 g/l; non-ionic surfactant emulsifiers & surfactants-noni other 196.0 g/l - adjuvant - defoliant additive | desiccant additive | fungicide additive | herbicide additive | insecticide additive | pyrethroid insecticid - tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

duluxgroup (australia) pty ltd - 4-(p-acetoxyphenyl)-2-butanone; malathion - vapour releasing product - 4-(p-acetoxyphenyl)-2-butanone acetate active 1.0 ml/wick; malathion organophosphorus-dithiophospha active 0.5 ml/wick - insecticide - orchard - general | apple orchard | apricot orchard | cherry orchard | citrus orchard | grapefruit orchard | lemon orchard | nas - queensland fruit fly - male | dacus tryoni

Malta - angļu - Medicines Authority

procter & gamble (health & beauty care) limited - camphor, pine oil, menthol - nasal stick - camphor 50 milligram(s) ; pine oil 10 milligram(s) ; menthol 125 milligram(s) - nasal preparations

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

restoration rockstar llc - tolnaftate (unii: 06kb629tkv) (tolnaftate - unii:06kb629tkv) - - proven clinically effective in the treatment of most athlete's foot (tinea pedis) & ringworm (tinea corporis). - helps prevent most athlete's foot with daily use. - for effective relief of itching, burning & cracking.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 60917 - bed incontinence system - the purewick? urine collection system is to be used with purewick? external catheters which are intended for non-invasive urine output management.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chadwick pharmaceuticals, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (nsaid) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10)]. diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. teratogenic effects: there are no adequate and w

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chadwick pharmaceuticals, inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)] . pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation risk summary use of nsaids, including diclofenac sodium, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including diclofenac sodium topical solution, in p

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chadwick pharmaceuticals, inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. risk summary use of nsaids, including diclofenac sodium, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of diclofenac sodium use between about 20 and 30 weeks of gestat

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

chadwick pharmaceuticals, inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. risk summary use of nsaids, including diclofenac sodium, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of diclofenac sodium use between about 20 and 30 weeks of gestat